Clarivate Plc (NYSE:CLVT) Insider James Gordon Samson Sells 50,000 Shares

Clarivate Plc (NYSE:CLVTGet Rating) insider James Gordon Samson sold 50,000 shares of the stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $14.25, for a total transaction of $712,500.00. Following the completion of the transaction, the insider now owns 838,787 shares in the company, valued at $11,952,714.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

James Gordon Samson also recently made the following trade(s):

  • On Wednesday, May 11th, James Gordon Samson sold 58,000 shares of Clarivate stock. The shares were sold at an average price of $13.91, for a total transaction of $806,780.00.
  • On Monday, March 14th, James Gordon Samson sold 16,000 shares of Clarivate stock. The stock was sold at an average price of $14.13, for a total value of $226,080.00.

Shares of CLVT stock opened at $14.66 on Wednesday. The firm has a fifty day moving average of $15.73 and a 200-day moving average of $18.64. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.87 and a quick ratio of 0.87. Clarivate Plc has a 12-month low of $11.71 and a 12-month high of $34.79.

Clarivate (NYSE:CLVTGet Rating) last announced its earnings results on Monday, May 9th. The company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.03. Clarivate had a negative net margin of 4.77% and a positive return on equity of 4.89%. The firm had revenue of $662.20 million during the quarter, compared to analyst estimates of $662.84 million. During the same period in the prior year, the business earned $0.13 EPS. The company’s revenue for the quarter was up 54.6% compared to the same quarter last year. Research analysts anticipate that Clarivate Plc will post 0.74 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of CLVT. Clearstead Advisors LLC bought a new stake in Clarivate in the 1st quarter valued at approximately $25,000. Elequin Capital LP acquired a new stake in shares of Clarivate in the first quarter valued at approximately $28,000. NEXT Financial Group Inc lifted its position in shares of Clarivate by 135.1% in the fourth quarter. NEXT Financial Group Inc now owns 1,615 shares of the company’s stock worth $38,000 after purchasing an additional 928 shares in the last quarter. Pinnacle Bancorp Inc. acquired a new position in Clarivate during the first quarter worth $48,000. Finally, Penserra Capital Management LLC bought a new position in Clarivate in the fourth quarter valued at $83,000. Institutional investors and hedge funds own 90.87% of the company’s stock.

A number of equities analysts have issued reports on the company. Zacks Investment Research upgraded Clarivate from a “sell” rating to a “hold” rating in a report on Tuesday. The Goldman Sachs Group decreased their price objective on shares of Clarivate from $23.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, April 19th. Morgan Stanley cut their target price on shares of Clarivate from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Friday, March 11th. Barclays lowered shares of Clarivate from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $25.00 to $16.00 in a report on Thursday, February 3rd. Finally, Citigroup downgraded Clarivate from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $35.00 to $16.00 in a research note on Friday, February 4th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from, Clarivate presently has an average rating of “Buy” and an average target price of $19.50.

Clarivate Company Profile (Get Rating)

Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis and Newport Integrity for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs.

Featured Articles

Insider Buying and Selling by Quarter for Clarivate (NYSE:CLVT)

Receive News & Ratings for Clarivate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarivate and related companies with's FREE daily email newsletter.